CN112752580B - 抗klrg1抗体 - Google Patents

抗klrg1抗体 Download PDF

Info

Publication number
CN112752580B
CN112752580B CN201980060735.4A CN201980060735A CN112752580B CN 112752580 B CN112752580 B CN 112752580B CN 201980060735 A CN201980060735 A CN 201980060735A CN 112752580 B CN112752580 B CN 112752580B
Authority
CN
China
Prior art keywords
seq
antibody
cdr
antibodies
abc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980060735.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN112752580A (zh
Inventor
斯蒂芬诺·V.·古洛
肯尼斯·埃文·汤普森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Apoco Ltd
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apoco Ltd, Brigham and Womens Hospital Inc filed Critical Apoco Ltd
Priority to CN202411978380.6A priority Critical patent/CN119638835A/zh
Publication of CN112752580A publication Critical patent/CN112752580A/zh
Application granted granted Critical
Publication of CN112752580B publication Critical patent/CN112752580B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980060735.4A 2018-09-17 2019-09-06 抗klrg1抗体 Active CN112752580B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411978380.6A CN119638835A (zh) 2018-09-17 2019-09-06 抗klrg1抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732329P 2018-09-17 2018-09-17
US62/732329 2018-09-17
PCT/US2019/050110 WO2020060781A1 (en) 2018-09-17 2019-09-06 Anti-klrg1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411978380.6A Division CN119638835A (zh) 2018-09-17 2019-09-06 抗klrg1抗体

Publications (2)

Publication Number Publication Date
CN112752580A CN112752580A (zh) 2021-05-04
CN112752580B true CN112752580B (zh) 2024-12-13

Family

ID=69887899

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980060735.4A Active CN112752580B (zh) 2018-09-17 2019-09-06 抗klrg1抗体
CN202411978380.6A Pending CN119638835A (zh) 2018-09-17 2019-09-06 抗klrg1抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411978380.6A Pending CN119638835A (zh) 2018-09-17 2019-09-06 抗klrg1抗体

Country Status (13)

Country Link
US (1) US12365735B2 (https=)
EP (1) EP3852779A4 (https=)
JP (2) JP7654548B2 (https=)
KR (1) KR102934267B1 (https=)
CN (2) CN112752580B (https=)
AU (1) AU2019344524A1 (https=)
BR (1) BR112021004553A2 (https=)
CA (1) CA3113069A1 (https=)
EA (1) EA202190647A1 (https=)
IL (2) IL281594B2 (https=)
MX (2) MX2021003119A (https=)
SG (1) SG11202102114UA (https=)
WO (1) WO2020060781A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021004553A2 (pt) 2018-09-17 2021-06-08 Abcuro, Inc. anticorpos anti-klrg1
WO2022056289A1 (en) * 2020-09-11 2022-03-17 National Jewish Health Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells
WO2022204529A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
CA3212311A1 (en) * 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
WO2024072872A2 (en) * 2022-09-27 2024-04-04 The Brigham And Women's Hospital, Inc. Klrg1 signalling therapy for infectious disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101663323A (zh) * 2006-12-27 2010-03-03 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
CN103347896A (zh) * 2010-09-02 2013-10-09 瓦西尼斯公司 抗cxcl13抗体和其使用方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
EP1858925A2 (en) 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
KR20160070165A (ko) 2008-02-08 2016-06-17 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
JP6152090B2 (ja) 2011-04-21 2017-06-21 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 視神経脊髄炎を処置するための組成物および方法
DK3424953T3 (en) 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
JPWO2012176765A1 (ja) 2011-06-24 2015-02-23 株式会社ペルセウスプロテオミクス 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体
WO2014177459A2 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
JP2017518958A (ja) 2014-03-19 2017-07-13 マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルＭａｃｋａｙ Ｍｅｄｉｃａｌ Ｆｏｕｎｄａｔｉｏｎ Ｔｈｅ Ｐｒｅｓｂｙｔｅｒｉａｎ Ｃｈｕｒｃｈ Ｉｎ Ｔａｉｗａｎ Ｍａｃｋａｙ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
WO2016009487A1 (ja) 2014-07-14 2016-01-21 三菱電機株式会社 空気調和装置
HUE068868T2 (hu) 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
AU2016334623A1 (en) 2015-10-07 2018-02-15 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory TNF receptor
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
JP2019518791A (ja) 2016-06-03 2019-07-04 ザ・ブリガム・アンド・ウィメンズ・ホスピタルＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ Ｋｌｒｇ１シグナリングセラピー
AU2017326003A1 (en) 2016-09-16 2019-04-11 Children's Medical Center Corporation KLRG1 depletion therapy
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
CN111093702A (zh) 2017-06-22 2020-05-01 财团法人生物技术开发中心 靶细胞依赖性T细胞的接合和活化型不对称异二聚Fc-ScFv融合抗体形式用于癌症治疗
WO2019169229A1 (en) 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
BR112021004553A2 (pt) 2018-09-17 2021-06-08 Abcuro, Inc. anticorpos anti-klrg1
AU2020272939A1 (en) 2019-04-09 2021-11-11 Abcuro, Inc. Killer cell lectin-like receptor subfamily G member 1 (KLRG1) depleting antibodies
CA3212311A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101663323A (zh) * 2006-12-27 2010-03-03 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
CN103347896A (zh) * 2010-09-02 2013-10-09 瓦西尼斯公司 抗cxcl13抗体和其使用方法

Also Published As

Publication number Publication date
IL281594B2 (en) 2026-02-01
MX2025008993A (es) 2025-09-02
JP2022501065A (ja) 2022-01-06
AU2019344524A1 (en) 2021-03-25
CN119638835A (zh) 2025-03-18
MX2021003119A (es) 2021-05-14
IL281594A (en) 2021-05-31
KR20210060477A (ko) 2021-05-26
SG11202102114UA (en) 2021-04-29
EP3852779A1 (en) 2021-07-28
US20210347899A1 (en) 2021-11-11
JP2024156878A (ja) 2024-11-06
US12365735B2 (en) 2025-07-22
IL323170A (en) 2025-11-01
EA202190647A1 (ru) 2021-09-09
CA3113069A1 (en) 2020-03-26
EP3852779A4 (en) 2022-06-08
WO2020060781A1 (en) 2020-03-26
CN112752580A (zh) 2021-05-04
BR112021004553A2 (pt) 2021-06-08
JP7654548B2 (ja) 2025-04-01
IL281594B1 (en) 2025-10-01
KR102934267B1 (ko) 2026-03-05

Similar Documents

Publication Publication Date Title
CN112752580B (zh) 抗klrg1抗体
JP4511943B2 (ja) Ｐｄ−１に対する抗体およびその使用
KR102522693B1 (ko) 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
JP4606739B2 (ja) 新規抗ｉｇｆ−ｉｒ抗体およびその使用
JP7368453B2 (ja) Ｐｄ－１およびｌａｇ－３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質
TW202132347A (zh) 針對cd3和bcma的抗體和自其製備的雙特異性結合蛋白
US20240383983A1 (en) Anti-B7-H4/Anti-4-1BB Bispecific Antibodies And Use Thereof
WO2015166105A2 (en) Ion channel modulators and uses thereof
KR20210042091A (ko) 항-l1cam 항체 및 이의 용도
KR20240026496A (ko) 항-넥틴4 항체 및 이를 포함하는 다중특이적 단백질 복합체
US20260125479A1 (en) Anti-klrg1 antibodies
EA049153B1 (ru) Антитела к klrg1
RU2782381C2 (ru) Высокоаффинные анти-pd-1 и анти-lag-3 антитела и полученные из них биспецифические связывающие белки
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
HK40060740A (en) Exosome-targeting bispecific antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20241008

Address after: Massachusetts, USA

Applicant after: THE BRIGHAM AND WOMEN'S Hospital Inc.

Country or region after: U.S.A.

Address before: 90 Bridge Street, Newton, Massachusetts, USA

Applicant before: Apoco Ltd.

Country or region before: U.S.A.

GR01 Patent grant
GR01 Patent grant